CN115010756A - 一种吲哚类有机膦化合物的合成方法 - Google Patents
一种吲哚类有机膦化合物的合成方法 Download PDFInfo
- Publication number
- CN115010756A CN115010756A CN202210801332.4A CN202210801332A CN115010756A CN 115010756 A CN115010756 A CN 115010756A CN 202210801332 A CN202210801332 A CN 202210801332A CN 115010756 A CN115010756 A CN 115010756A
- Authority
- CN
- China
- Prior art keywords
- indole
- compound
- reaction
- solvent
- synthesizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title claims abstract description 69
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 title claims abstract description 47
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 title claims abstract description 47
- -1 phosphine compound Chemical class 0.000 title claims abstract description 35
- 238000010189 synthetic method Methods 0.000 title claims description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 title abstract description 9
- 229910000073 phosphorus hydride Inorganic materials 0.000 title abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims abstract description 86
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000002904 solvent Substances 0.000 claims abstract description 36
- YFPJFKYCVYXDJK-UHFFFAOYSA-N Diphenylphosphine oxide Chemical compound C=1C=CC=CC=1[P+](=O)C1=CC=CC=C1 YFPJFKYCVYXDJK-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000003054 catalyst Substances 0.000 claims abstract description 16
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 11
- 229910052751 metal Inorganic materials 0.000 claims abstract description 9
- 239000002184 metal Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Natural products CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003513 alkali Substances 0.000 claims abstract description 6
- 238000007259 addition reaction Methods 0.000 claims abstract description 4
- 238000005882 aldol condensation reaction Methods 0.000 claims abstract description 4
- 238000006297 dehydration reaction Methods 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 57
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 51
- 239000000047 product Substances 0.000 claims description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- 239000012043 crude product Substances 0.000 claims description 26
- 238000001914 filtration Methods 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 14
- 238000003818 flash chromatography Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- 238000012544 monitoring process Methods 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 8
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 8
- 229940126062 Compound A Drugs 0.000 claims description 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 238000004809 thin layer chromatography Methods 0.000 claims description 4
- 239000002274 desiccant Substances 0.000 claims description 3
- 150000003003 phosphines Chemical class 0.000 claims description 3
- GEKLDGQKEZAPFZ-UHFFFAOYSA-N 2-(ethylamino)-1-(3-methylphenyl)propan-1-one Chemical compound CCNC(C)C(=O)C1=CC=CC(C)=C1 GEKLDGQKEZAPFZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 8
- 238000001308 synthesis method Methods 0.000 abstract description 6
- 150000002903 organophosphorus compounds Chemical class 0.000 abstract description 5
- 230000000975 bioactive effect Effects 0.000 abstract description 2
- 239000003446 ligand Substances 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 150000008062 acetophenones Chemical class 0.000 description 11
- 230000008034 disappearance Effects 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 238000004821 distillation Methods 0.000 description 9
- 229910052698 phosphorus Inorganic materials 0.000 description 7
- 239000011574 phosphorus Substances 0.000 description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical group [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000005654 Michaelis-Arbuzov synthesis reaction Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- GINJFDRNADDBIN-FXQIFTODSA-N bilanafos Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCP(C)(O)=O GINJFDRNADDBIN-FXQIFTODSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000004050 enoyl group Chemical group 0.000 description 2
- 239000003063 flame retardant Substances 0.000 description 2
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- UZKBSZSTDQSMDR-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]piperazine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)N1CCNCC1 UZKBSZSTDQSMDR-UHFFFAOYSA-N 0.000 description 1
- RNFJDJUURJAICM-UHFFFAOYSA-N 2,2,4,4,6,6-hexaphenoxy-1,3,5-triaza-2$l^{5},4$l^{5},6$l^{5}-triphosphacyclohexa-1,3,5-triene Chemical compound N=1P(OC=2C=CC=CC=2)(OC=2C=CC=CC=2)=NP(OC=2C=CC=CC=2)(OC=2C=CC=CC=2)=NP=1(OC=1C=CC=CC=1)OC1=CC=CC=C1 RNFJDJUURJAICM-UHFFFAOYSA-N 0.000 description 1
- HTFNVAVTYILUCF-UHFFFAOYSA-N 2-[2-ethoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino]-5-methyl-11-methylsulfonylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(c2n1)S(C)(=O)=O)C(=O)N1CCC(CC1)N1CCN(C)CC1 HTFNVAVTYILUCF-UHFFFAOYSA-N 0.000 description 1
- UOXJNGFFPMOZDM-UHFFFAOYSA-N 2-[di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid Chemical compound CC(C)N(C(C)C)CCSP(C)(O)=O UOXJNGFFPMOZDM-UHFFFAOYSA-N 0.000 description 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000946904 Streptomyces fragilis Species 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000012658 bimolecular nucleophilic substitution Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
本发明属于有机化学合成技术领域,公开一种吲哚类有机膦化合物的合成方法,其包括以下步骤:首先,以2‑吲哚甲醛类化合物和苯乙酮类化合物为原料,溶于第一溶剂中,在碱催化剂条件下进行羟醛缩合脱水反应,得到吲哚烯酰基类化合物;然后,将二苯基氧膦、吲哚烯酰基类化合物溶于第二溶剂中,在金属盐催化剂条件下进行加成反应,得到目标产物。本发明条件温和,反应迅速,原子经济性好,产率高,绿色高效,在有机合成领域具有广阔的应用前景,为复杂膦配体及生物活性有机磷化合物的合成提供新途径。
Description
技术领域
本发明属于有机化学合成技术领域,尤其是涉及一种吲哚类有机膦化合物的合成方法。
背景技术
有机磷化合物因其独特的理化性质在有机合成、医药、农药、材料以及生命科学中都有着广泛的应用。含磷有机分子具有抗菌、抗肿瘤等药物活性,因此被用于组织蛋白酶抑制剂、抗疟疾药、钙拮抗剂等药物的主要活性成分。有些有机含磷化合物存在于天然产物中,例如,双丙胺膦(Bialaphos)是从吸水链霉菌(Streptomyces hygroscopicus)发酵液中分离、提纯的一种三肽天然产物,是一类非选择性除草剂;磷霉素(Fosfomycin)最初从Streptomyces fradicle中分离,对革兰氏阳性和阴性菌有效,是一类广泛使用的商品化抗生素。有机含磷化合物在功能材料领域也发挥着重要作用,已被大量研究和使用的有机含磷阻燃剂,因其无卤无毒且高效的特点在阻燃材料领域得以普遍认可。
另一方面,含吲哚环结构的化合物因其特有的化学结构,使其在抗高血压、抗增殖、抗病毒、抗肿瘤、镇痛、抗炎、抗菌等多个治疗领域的药物中表现出了良好的生物活性。例如,长春碱(VLB)是一种二聚吲哚的衍生物,作用于微管蛋白会影响肿瘤细胞的有丝分裂,进而抑制肿瘤细胞的增殖。褪黑素是典型的吲哚类激素,它是一种生理性肿瘤抑制剂。
鉴于有机磷化合物与吲哚环骨架的重要性,如何高效快捷地构建同时含有机磷和吲哚环活性单元的新型分子,实现活性基团的高效融合,从而提升其潜在的生物活性,一直是有机合成和药物学的研究重点之一。早期发展的米歇尔–阿尔布佐夫反应(Michaelis-Arbuzov反应)是通过C-P键构建合成含磷化合物的主要方法,即三价的磷酸酯与卤代烷烃发生双分子亲核取代反应(SN2)生成五价的烷基磷酸酯,但是,原子经济性差、反应条件苛刻、底物范围窄等缺点限制了该类反应在有机含磷化合物合成中的应用。
P-H键加成烯键和炔键氢膦化,是构筑C-P键的优良途径,利用磷-氢化合物直接构建有机磷化合物,可以避免使用对水氧敏感的磷卤试剂,且反应的原子经济性较高,更为绿色环保。这类加成反应一般都是在碱、金属催化剂或自由基引发剂催化下进行,但是这些合成方法仍然存在催化剂昂贵、反应条件要求无水无氧、副产物较多等缺陷。
发明内容
为解决上述问题,本发明的目的是提供一种高效、经济、环境友好的吲哚类有机膦化合物的合成方法。
为实现上述发明目的,本发明采用如下技术方案:
一种吲哚类有机膦化合物的合成方法,其包括以下步骤:
S1、以2-吲哚甲醛类化合物A和苯乙酮类化合物B为原料,溶于第一溶剂中,在碱催化剂条件下进行羟醛缩合脱水反应,得到吲哚烯酰基类化合物C;
反应路线如下:
其中,R1选自2-Me、3-Me、4-Me、2-Cl、3-Cl、4-Cl、H中的一种;Ar1选自2-MeC6H4、3-MeC6H4、4-MeC6H4、3-BrC6H4、4-MeOC6H4、naphthalene、thianaphthene、furan、pyrrole中的一种;
S2、将二苯基氧膦、步骤S1中得到的吲哚烯酰基类化合物C溶于第二溶剂中,在金属盐催化剂条件下进行加成反应,得到目标产物D;
反应路线如下:
进一步地,上述的步骤S1中,2-吲哚甲醛类化合物A和苯乙酮类化合物B的摩尔比为1:2~2:1mmol,2-吲哚甲醛类化合物A、第一溶剂和碱催化剂的用量之比为1mmol:5~15mL:1~2mmol。
进一步地,上述的步骤S1中,第一溶剂为乙醇、甲醇、二氯甲烷、乙酸乙酯中的一种。
进一步地,上述的步骤S1中,碱催化剂为0.5~1.5mol/L的NaOH溶液或KOH溶液。
进一步地,上述的步骤S1中,反应温度为0~室温,反应时间为1.5~3h。
进一步地,上述的步骤S2中,二苯基氧膦和吲哚烯酰基类化合物C的摩尔比为1:1~5:1mmol,吲哚烯酰基类化合物C、第二溶剂、金属盐催化剂的用量之比为1mmol:2~8mL:1~5mmol。
进一步地,上述的步骤S2中,第二溶剂为二氯甲烷、甲苯、N,N-二甲基甲酰胺、正己烷中的一种。
进一步地,上述的步骤S2中,金属盐催化剂为Cs2CO3、Na2CO3、NaHCO3、K2CO3、K3PO4、Na3PO4、Cu(OAc)2中的一种。
进一步地,上述的步骤S2中,反应温度为室温,反应时间为2~5h。
进一步地,上述的吲哚类有机膦化合物的合成方法,其步骤S2中,用薄层色谱TLC监测反应进程,待反应物完全消失后,将反应液倒入水中,再用萃取剂萃取,合并萃取液;萃取液用干燥剂干燥,过滤、减压蒸馏,得粗产物;然后将粗产物用快速柱色谱法纯化,获得目标化合物。
更进一步地,上述的萃取剂为二氯甲烷、乙酸乙酯、乙醚或氯仿。
更进一步地,上述的干燥剂为无水硫酸钠、无水氯化钙或无水硫酸镁。
更进一步地,上述的快速柱色谱法纯化中,洗脱剂为石油醚、乙酸乙酯,石油醚、乙酸乙酯的体积比为1:1。
由于采用如上所述的技术方案,本发明具有如下优越性:
本发明吲哚类有机膦化合物的合成方法,其以2-吲哚甲醛类化合物为起始原料,与苯乙酮类化合物经羟醛缩合脱水反应得到带有吲哚骨架的不对称烯烃,即吲哚烯酰基类化合物,再利用金属盐催化2-烯基吲哚酮化合物与二苯基氧膦的P-H键进行亲核加成反应,构筑C(sp3)-P键,得到吲哚类有机膦化合物;原料来源广,结构多样化,易操作,成本低,简单易行、安全,条件温和,反应迅速,原子经济性好,产率高,绿色高效,在有机合成领域具有广阔的应用前景,为复杂膦配体及生物活性有机磷化合物的合成提供新途径。
具体实施方式
参照以下实施例可以对本发明作进一步详细说明;但是,以下实施例仅仅是例证,本发明并不局限于这些实施例。
实施例1
步骤一、在25mL的圆底烧瓶中加入2mmol苯乙酮类化合物B1,用9mL乙醇溶解,0℃条件下慢慢滴加4mL 0.5mol/L NaOH溶液,室温下搅拌反应1h;然后加入2mmol 2-吲哚甲醛类化合物A1,室温搅拌反应1h,大量黄色固体生成,过滤,乙醇洗涤,减压蒸馏除去溶剂,得到1.85mmol吲哚烯酰基类化合物C1;
具体反应式为:
步骤二、在25mL的圆底烧瓶中加入二苯基氧膦1.5mmol和制备得到的吲哚烯酰基类化合物C1 0.5mmol,用1mL二氯甲烷溶解,再加入Cs2CO3 1mmol,室温(r.t.)下搅拌反应2h;监测反应底物消失后,将反应液倒入水中,用二氯甲烷萃取三次(3×10mL),合并萃取液,然后用无水硫酸钠干燥,过滤,减压蒸馏除去溶剂,得粗产物;然后将粗产物用快速柱色谱法纯化,洗脱剂为体积比1:1的石油醚和乙酸乙酯,即得目标产物D1,产率为92%。
具体反应式为:
目标产物D1的1H NMR(CDCl3,400MHz):δ7.84-7.80(m,2H),7.76(d,J=7.8,2H),7.50-7.38(m,4H),7.29(m,5H),7.21(s,1H),7.13(td,J=7.6,2.8Hz,2H),6.91(dd,J=24,8.8Hz,2H),6.50(d,J=3.2Hz,1H),4.52(t,J=8.8Hz,1H),4.06(ddd,J=18.0,10.4,4.0Hz,1H),3.46(ddd,J=18.0,9.2,2.0Hz,1H),3.24(s,3H),2.31(s,3H);
目标产物D1的13C NMR(100MHz,CDCl3):δ196.70(d,J=12.9Hz),135.83(d,J=82.4Hz),134.65(d,J=4.8Hz),133.45,132.35(d,J=2.5Hz),131.93(d,J=2.6Hz),131.17(d,J=9.1Hz),129.02(d,J=11.2Hz),128.58(d,J=4.3Hz),128.21(d,J=11.7Hz),128.12,127.72(d,J=2.7Hz),122.84,119.95,108.80,101.61(d,J=5.1Hz),39.91,34.89(d,J=35.8Hz),34.22(d,J=70.5Hz),31.46,30.23,29.13;
目标产物D1的31P NMR(162MHz,CDCl3):δ31.26.
实施例2
步骤一、在25mL的圆底烧瓶中加入2mmol苯乙酮类化合物B2,用8mL乙醇溶解,5℃条件下慢慢滴加1.8mL 0.7mol/L NaOH溶液,室温下搅拌反应1h;然后加入1mmol 2-吲哚甲醛类化合物A2,室温搅拌反应50min,大量黄色固体生成,过滤,乙醇洗涤,减压蒸馏除去溶剂,得到0.93mmol吲哚烯酰基类化合物C2;
具体反应式为:
步骤二、在25mL的圆底烧瓶中加入二苯基氧膦2.0mmol和制备得到的吲哚烯酰基类化合物C2 1.0mmol,用3mL二氯甲烷溶解,再加入Cs2CO3 2.0mmol,室温(r.t.)下搅拌反应2.5h;监测反应底物消失后,将反应液倒入水中,用二氯甲烷萃取三次(3×10mL),合并萃取液,然后用无水氯化钙干燥,过滤,减压蒸馏除去溶剂,得粗产物;然后将粗产物用快速柱色谱法纯化,洗脱剂为体积比1:1的石油醚和乙酸乙酯,即得目标产物D2,产率为93%。
具体反应式为:
目标产物D2的H NMR(400MHz,CDCl3):δ7.75-7.81(m,2H),7.75(d,J=7.6,2H),7.50-7.39(m,5H),7.32-7.28(m,5H),7.14(td,J=7.6,2.8Hz,2H),6.82(s,2H),6.79(d,J=8Hz,1H),6.53(d,J=2.4Hz,1H),4.53(t,J=8.8Hz,1H),3.96(ddd,J=18.0,10.8,4.0Hz,1H),3.46(ddd,J=18.0,9.2,1.6Hz,1H),3.24(s,3H),2.35(s,3H);
目标产物D2的13C NMR(100MHz,CDCl3):δ195.67(d,J=12.9Hz),136.31(d,J=11.2Hz),132.92(d,J=4.5Hz),132.38 131.28(d,J=2.3Hz),131.93(d,J=2.5Hz),130.70(d,J=7.7Hz),120.12(d,J=9.2Hz),129.89,127.97(d,J=11.2Hz),127.53,127.23,127.11(d,J=4.3Hz),124.51(d,J=2.1Hz),120.09,118.88,108.09,100.97(d,J=5.2Hz),38.94,33.04(d,J=70.7Hz),28.66(d,J=68.0Hz),21.65,20.84;
目标产物D2的31P NMR(162MHz,CDCl3):δ31.31.
实施例3
步骤一、在25mL的圆底烧瓶中加入3mmol苯乙酮类化合物B3,用13mL甲醇溶解,10℃条件下慢慢滴加3.0mL 1.0mol/L KOH溶液,室温下搅拌反应1.2h;然后加入2.5mmol 2-吲哚甲醛类化合物A3,室温搅拌反应40min,大量黄色固体生成,过滤,乙醇洗涤,减压蒸馏除去溶剂,得到2.34mmol吲哚烯酰基类化合物C3;
具体反应式为:
步骤二、在25mL的圆底烧瓶中加入二苯基氧膦2.5mmol和制备得到的吲哚烯酰基类化合物C3 1.0mmol,用4mL甲苯溶解,再加入Na2CO3 2.0mmol,室温(r.t.)下搅拌反应2.5h;监测反应底物消失后,将反应液倒入水中,用乙酸乙酯萃取三次(3×10mL),合并萃取液,然后用无水硫酸钠干燥,过滤,减压蒸馏除去溶剂,得粗产物;然后将粗产物用快速柱色谱法纯化,洗脱剂为体积比1:1的石油醚和乙酸乙酯,即得目标产物D3,产率为91%。
具体反应式为:
目标产物D3的1H NMR(400MHz,CDCl3):δ7.85-7.81(m,2H),7.77(d,J=8.0,2H),7.64-7.59(m,3H),7.42-7.38(m,4H),7.30-7.26(m,3H),7.15-7.13(m,2H),6.80(t,J=7.6Hz,1H),6.53(d,J=6.4Hz,1H),4.53(t,J=9.6Hz,1H),3.96(ddd,J=18.0,10.8,4.0Hz,1H),3.51(s,3H),3.46(dd,J=17.6,9.2Hz,1H),2.51(s,3H);
目标产物D3的13C NMR(100MHz,CDCl3):δ196.78(d,J=13.0Hz),136.21(d,J=11.4Hz),134.87(d,J=4.7Hz),133.48 132.39(d,J=2.8Hz),131.90(d,J=2.6Hz),131.78(d,J=8.4Hz),131.20(d,J=11.4Hz),130.78(d,J=11.4Hz),129.02(d,J=3.6Hz),128.91(d,J=5.3Hz),128.60,128.46(d,J=2.3Hz),128.26,128.14,124.51,120.61,119.41,118.56,102.98(d,J=5Hz),39.78,34.01(d,J=70.3Hz),32.06,31.45,30.22,29.70,20.52;
目标产物D3的31P NMR(162MHz,CDCl3):δ31.51.
实施例4
步骤一、在25mL的圆底烧瓶中加入2mmol苯乙酮类化合物B4,用12mL乙醇溶解,15℃条件下慢慢滴加3.5mL 1.0mol/L NaOH溶液,室温下搅拌反应1h;然后加入2.5mmol 2-吲哚甲醛类化合物A4,室温搅拌反应1h,大量黄色固体生成,过滤,乙醇洗涤,减压蒸馏除去溶剂,得到2.36mmol吲哚烯酰基类化合物C4;
具体反应式为:
步骤二、在25mL的圆底烧瓶中加入二苯基氧膦3.5mmol和制备得到的吲哚烯酰基类化合物C4 1.0mmol,用3mL二氯甲烷溶解,再加入Cs2CO3 2.0mmol,室温(r.t.)下搅拌反应3h;监测反应底物消失后,将反应液倒入水中,用乙酸乙酯萃取三次(3×10mL),合并萃取液,然后用无水硫酸钠干燥,过滤,减压蒸馏除去溶剂,得粗产物;然后将粗产物用快速柱色谱法纯化,洗脱剂为体积比1:1的石油醚和乙酸乙酯,即得目标产物D4,产率为89%。
具体反应式为:
目标产物D4的1H NMR(400MHz,CDCl3):δ7.83-7.77(m,4H),7.55-7.51(m,1H),7.64-7.59(m,3H),7.49-7.42(m,3H),7.34-7.29(m,5H),7.18-7.13(m,2H),6.96-6.93(m,J=7.6Hz,3H),6.65(d,J=7.0Hz,1H),4.52(t,J=9.2Hz,1H),3.98(ddd,J=18.2,11.2,4.0Hz,1H),3.46(ddd,J=18.2,9.2,2Hz,1H),3.29(s,3H);
目标产物D4的13C NMR(100MHz,CDCl3):δ195.57(d,J=12.8Hz),136.61,135.03,134.73(d,J=5.4Hz),132.57,131.44(d,J=2.6Hz),131.04(d,J=2.6Hz),130.73(d,J=8.3Hz),130.14(d,J=11.4Hz),128.04(d,J=11.2Hz),127.62,127.30(d,J=11.7Hz),127.12,125.36,124.51,120.733,118.25,106.73,99.64(d,J=5.0Hz),38.92,33.36,32.66,28.52;
目标产物D4的31P NMR(162MHz,CDCl3):δ30.93.
实施例5
步骤一、在25mL的圆底烧瓶中加入4mmol苯乙酮类化合物B5,用15mL二氯甲烷溶解,20℃条件下慢慢滴加2mL 1.0mol/L KOH溶液,室温下搅拌反应1h;然后加入2mmol 2-吲哚甲醛类化合物A5,室温搅拌反应1.5h,大量黄色固体生成,过滤,乙醇洗涤,减压蒸馏除去溶剂,得到1.90mmol吲哚烯酰基类化合物C5;
具体反应式为:
步骤二、在25mL的圆底烧瓶中加入二苯基氧膦3.0mmol和制备得到的吲哚烯酰基类化合物C5 1.0mmol,用4mL二氯甲烷溶解,再加入Cs2CO3 2.5mmol,室温(r.t.)下搅拌反应3.5h;监测反应底物消失后,将反应液倒入水中,用乙醚萃取三次(3×10mL),合并萃取液,然后用无水硫酸镁干燥,过滤,减压蒸馏除去溶剂,得粗产物;然后将粗产物用快速柱色谱法纯化,洗脱剂为体积比1:1的石油醚和乙酸乙酯,即得目标产物D5,产率为85%。
具体反应式为:
目标产物D5的1H NMR(400MHz,CDCl3):δ7.81(t,8.8Hz,2H),7.50(d,J=7.2Hz,1H),7.46-7.43(m,4H),7.33-7.28(m,3H),7.23-7.28(m,3H),7.23-7.19(t,J=7.2Hz,1H),7.17-7.08(m,4H),7.05-7.02(m,3H),6.99-6.95(m,1H),6.56(d,J=2.4Hz,1H),4.52(t,J=9.0Hz,1H),3.82(ddd,J=18.0,10.8,2.4Hz,1H),3.41(ddd,J=18.0,9.6,2.4Hz,1H),3.23(s,3H),2.11(s,3H);
目标产物D5的13C NMR(100MHz,CDCl3):δ199.38(d,J=14.6Hz),137.14,135.94,131.31,130.90,130.81(d,J=7.4Hz),130.65(d,J=9.3Hz),130.15(d,J=9.4Hz),127.93(d,J=10.4Hz),124.67,(d,J=8.3Hz),120.22,119.30,118.37,108.03,101.24,41.42,33.57,33.57,32.86,28.67,28.07,19.94;
目标产物D5的31P NMR(162MHz,CDCl3):δ30.98.
实施例6
步骤一、在25mL的圆底烧瓶中加入2mmol苯乙酮类化合物B6,用10mL乙醇溶解,0℃条件下慢慢滴加2mL 0.5mol/L NaOH溶液,室温下搅拌反应1h;然后加入1mmol 2-吲哚甲醛类化合物A6,室温搅拌反应1h,大量黄色固体生成,过滤,乙醇洗涤,减压蒸馏除去溶剂,得到0.95mmol吲哚烯酰基类化合物C6;
具体反应式为:
步骤二、在25mL的圆底烧瓶中加入二苯基氧膦1.5mmol和制备得到的吲哚烯酰基类化合物C6 1.0mmol,用1mL二氯甲烷溶解,再加入NaHCO3 1mmol,室温(r.t.)下搅拌反应2h;监测反应底物消失后,将反应液倒入水中,用二氯甲烷萃取三次(3×10mL),合并萃取液,然后用无水硫酸钠干燥,过滤,减压蒸馏除去溶剂,得粗产物;然后将粗产物用快速柱色谱法纯化,洗脱剂为体积比1:1的石油醚和乙酸乙酯,即得目标产物D6,产率为88%。
具体反应式为:
目标产物D6的1H NMR(400MHz,CDCl3):δ7.96-7.83(m,2H),7.66-7.60(m,2H),7.60-7.47(m,4H),7.40-7.27(m,4H),7.23(d,J=7.2Hz,1H),7.17(td,J=7.8,3.0Hz,2H),7.13-7.06(m,2H),7.01(ddd,J=7.8,5.6,2.4Hz,1H),6.69(d,J=2.8Hz,1H),4.61(t,J=8.6Hz,1H),4.06(ddd,J=18.0,10.6,3.6Hz,1H),3.46(ddd,J=18.0,9.4,2.0Hz,1H),3.34(s,3H),2.31(s,3H);
目标产物D6的13C NMR(100MHz,CDCl3)δ196.81(d,J=13.2Hz),138.46,136.58(d,J=74.5Hz),134.70(d,J=5.6Hz),134.25,132.37(d,J=2.4Hz),131.92(d,J=2.4Hz),131.72(d,J=8.4Hz),131.05(d,J=9.2Hz),129.01(d,J=11.2Hz),128.62(d,J=25.0Hz),128.21(d,J=11.8Hz),127.72(d,J=2.4Hz),125.29,121.18,120.30,119.83,109.07,102.18(d,J=5.0Hz),40.01,33.69(d,J=71.2Hz),29.07,21.21;
目标产物D6的31P NMR(162MHz,CDCl3)δ31.46.
实施例7
步骤一、在25mL的圆底烧瓶中加入2mmol苯乙酮类化合物B7,用15mL甲醇溶解,5℃条件下慢慢滴加2.5mL 0.8mol/L NaOH溶液,室温下搅拌反应1.5h;然后加入1.5mmol 2-吲哚甲醛类化合物A7,室温搅拌反应1h,大量黄色固体生成,过滤,乙醇洗涤,减压蒸馏除去溶剂,得到1.41mmol吲哚烯酰基类化合物C7;
具体反应式为:
步骤二、在25mL的圆底烧瓶中加入二苯基氧膦2mmol和制备得到的吲哚烯酰基类化合物C7 1mmol,用3mL N,N-二甲基甲酰胺溶解,再加入Na2CO32mmol,室温(r.t.)下搅拌反应3h;监测反应底物消失后,将反应液倒入水中,用乙酸乙酯萃取三次(3×10mL),合并萃取液,然后用无水氯化钙干燥,过滤,减压蒸馏除去溶剂,得粗产物;然后将粗产物用快速柱色谱法纯化,洗脱剂为体积比1:1的石油醚和乙酸乙酯,即得目标产物D7,产率为86%。
具体反应式为:
目标产物D7的1H NMR(400MHz,CDCl3):δ7.91(t,8.8Hz,2H),7.69(d,J=8.4Hz,1H),7.62-7.54(m,2H),7.53-7.50(m,3H),7.20(td,J=7.6,2.8Hz,2H),7.14-7.09(m,2H),7.06-7.02(m,4H),6.67(d,J=2.4Hz,1H),4.58(t,J=9.2Hz,1H),4.00(ddd,J=18.0,10.8,4.4Hz,1H),3.47(ddd,J=18.0,9.2,1.6Hz,1H),3.34(s,3H);
目标产物D7的13C NMR(100MHz,CDCl3):δ195.80(d,J=13.0Hz),136.92,134.51(d,J=4.9Hz),132.45(d,J=2.6Hz),132.01(d,J=2.6Hz),131.73(d,J=8.4Hz),131.10(d,J=9.2Hz),130.85,130.49,129.61,129.08(d,J=11.2Hz),128.78,128.29(d,J=11.6Hz),127.64(d,J=2.4Hz),121.30,119.45,109.09,102.13(d,J=5.1Hz),60.39,53.43,39.87,34.15,33.45,29.08,21.06,14.22;
目标产物D7的31P NMR(162MHz,CDCl3):δ31.09.
实施例8
步骤一、在50mL的圆底烧瓶中加入2mmol苯乙酮类化合物B8,用20mL乙醇溶解,10℃条件下慢慢滴加2.5mL 1.0mol/L KOH溶液,室温下搅拌反应1h;然后加入2mmol 2-吲哚甲醛类化合物A8,室温搅拌反应1.5h,大量黄色固体生成,过滤,乙醇洗涤,减压蒸馏除去溶剂,得到1.86mmol吲哚烯酰基类化合物C8;
具体反应式为:
步骤二、在25mL的圆底烧瓶中加入二苯基氧膦3mmol和制备得到的吲哚烯酰基类化合物C8 1mmol,用2mL N,N-二甲基甲酰胺溶解,再加入K2CO32mmol,室温(r.t.)下搅拌反应3h;监测反应底物消失后,将反应液倒入水中,用乙醚萃取三次(3×10mL),合并萃取液,然后用无水硫酸镁干燥,过滤,减压蒸馏除去溶剂,得粗产物;然后将粗产物用快速柱色谱法纯化,洗脱剂为体积比1:1的石油醚和乙酸乙酯,即得目标产物D8,产率为84%。
具体反应式为:
目标产物D8的1H NMR(400MHz,CDCl3):δ7.91(t,8.8Hz,2H),7.60(d,J=6.8Hz,1H),7.57-7.51(m,3H),7.46(d,J=8.0Hz,1H),7.40-7.28(m,5H),7.23-7.19(td,J=7.6,2.8Hz,2H),7.15-7.09(m,2H),7.06-7.02(m,2H),6.67(d,J=2.4Hz,1H),4.61(t,J=9.2Hz,1H),3.82(ddd,J=18.0,10.8,4.0Hz,1H),3.78(s,3H),3.51(ddd,J=18.0,9.6,1.6Hz,1H),3.34(s,3H);
目标产物D8的13C NMR(100MHz,CDCl3):δ196.56(d,J=13.1Hz),159.77,137.51,136.93,134.66(d,J=5.1Hz),132.40(d,J=2.7Hz),131.96(d,J=2.6Hz),131.75(d,J=8.3Hz),131.12(d,J=9.2Hz),129.61,129.05(d,J=11.2Hz),128.27(d,J=11.6Hz),127.69(d,J=2.4Hz),121.21,120.83,120.29,119.38,112.02,109.08,102.17(d,J=5.1Hz),55.45,40.07,34.19,33.48,29.71,29.07;
目标产物D8的31P NMR(162MHz,CDCl3):δ31.22.
实施例9
步骤一、在25mL的圆底烧瓶中加入1.5mmol苯乙酮类化合物B9,用12mL二氯甲烷溶解,15℃条件下慢慢滴加2mL 1.0mol/L KOH溶液,室温下搅拌反应1.5h;然后加入1mmol 2-吲哚甲醛类化合物A9,室温搅拌反应1.5h,大量黄色固体生成,过滤,乙醇洗涤,减压蒸馏除去溶剂,得到0.92mmol吲哚烯酰基类化合物C9;
具体反应式为:
步骤二、在25mL的圆底烧瓶中加入二苯基氧膦4mmol和制备得到的吲哚烯酰基类化合物C9 1mmol,用2mL正己烷溶解,再加入K3PO4 3mmol,室温(r.t.)下搅拌反应3.5h;监测反应底物消失后,将反应液倒入水中,用氯仿萃取三次(3×10mL),合并萃取液,然后用无水硫酸镁干燥,过滤,减压蒸馏除去溶剂,得粗产物;然后将粗产物用快速柱色谱法纯化,洗脱剂为体积比1:1的石油醚和乙酸乙酯,即得目标产物D9,产率为81%。
具体反应式为:
目标产物D9的1H NMR(400MHz,CDCl3):δ8.42(s,3H),7.98(t,J=8.4Hz,2H),7.91-7.85(m,2H),7.78-7.76(m,2H),7.59-7.48(m,6H),7.38-7.32(m,3H),7.20-7.16(td,J=7.6,2.8Hz,2H),7.11-7.10(m,2H),7.05-7.00(m,1H),6.78(d,J=2.4Hz,1H),4.69(t,J=8.8Hz,1H),4.28(ddd,J=18.0,11.2,4.0Hz,1H),3.63(ddd,J=17.6,9.2,1.2Hz,1H),3.72(s,3H);
目标产物D9的13C NMR(100MHz,CDCl3):δ196.56(d,J=13.0Hz),136.95,135.69,134.70(d,J=4.7Hz),133.45,132.46(d,J=7.6Hz),132.37,129.13(d,J=11.2Hz),128.75,128.46,128.30(d,J=11.6Hz),127.71,126.91,123.48,121.22,120.34,119.40,109.10,102.22(d,J=5.3Hz),39.95,34.13,33.42,29.12;
目标产物D9的31P NMR(162MHz,CDCl3):δ31.52.
实施例10
步骤一、在50mL的圆底烧瓶中加入2mmol苯乙酮类化合物B10,用25mL乙醇溶解,20℃条件下慢慢滴加2mL 1.5mol/L NaOH溶液,室温下搅拌反应1h;然后加入2mmol 2-吲哚甲醛类化合物A10,室温搅拌反应1h,大量黄色固体生成,过滤,乙醇洗涤,减压蒸馏除去溶剂,得到1.81mmol吲哚烯酰基类化合物C10;
具体反应式为:
步骤二、在25mL的圆底烧瓶中加入二苯基氧膦5mmol和制备得到的吲哚烯酰基类化合物C10 1mmol,用5mL二氯甲烷溶解,再加入Na3PO4 5mmol,室温(r.t.)下搅拌反应4h;监测反应底物消失后,将反应液倒入水中,用乙酸乙酯萃取三次(3×10mL),合并萃取液,然后用无水氯化钙干燥,过滤,减压蒸馏除去溶剂,得粗产物;然后将粗产物用快速柱色谱法纯化,洗脱剂为体积比1:1的石油醚和乙酸乙酯,即得目标产物D10,产率为73%。
具体反应式为:
目标产物D10的1H NMR(400MHz,CDCl3):δ7.89-7.86(m,2H),7.78(d,J=8.0Hz,1H),7.72(d,J=8.0Hz,1H),7.54-7.45(m,4H),7.37-7.27(m,4H),7.19(s,1H),7.15-7.11(m,2H),7.05-7.02(m,2H),6.98-6.94(m,1H),6.69(d,J=2.4Hz,1H),4.54(t,J=8.8Hz,1H),4.08(ddd,J=17.6,11.2,4.0Hz,1H),3.49(ddd,J=17.2,8.8,1.2Hz,1H),3.26(s,3H);
目标产物D10的13C NMR(100MHz,CDCl3):δ190.18,141.56,137.90,136.95,135.93,131.45(d,J=2.7Hz),130.99(d,J=2.5Hz),130.73(d,J=8.3Hz),130.04(d,J=9.2Hz),128.46,128.10(d,J=11.2Hz),127.28(d,J=11.7Hz),126.65,125.10,124.05,121.84,120.26,119.32,118.39,108.08,101.31,52.39,39.24,33.10,32.40,28.68,26.19,21.67,17.43;
目标产物D10的31P NMR(162MHz,CDCl3):δ31.14.
实施例11
步骤一、在50mL的圆底烧瓶中加入2mmol苯乙酮类化合物B11,用30mL乙醇溶解,20℃条件下慢慢滴加2.5mL 1.5mol/L NaOH溶液,室温下搅拌反应2.5h;然后加入2mmol 2-吲哚甲醛类化合物A11,室温搅拌反应0.5h,大量黄色固体生成,过滤,乙醇洗涤,减压蒸馏除去溶剂,得到1.80mmol吲哚烯酰基类化合物C11;
具体反应式为:
步骤二、在25mL的圆底烧瓶中加入二苯基氧膦5mmol和制备得到的吲哚烯酰基类化合物C11 1mmol,用8mL甲苯溶解,再加入Cu(OAc)2 3mmol,室温(r.t.)下搅拌反应3h;监测反应底物消失后,将反应液倒入水中,用二氯甲烷萃取三次(3×10mL),合并萃取液,然后用无水硫酸钠干燥,过滤,减压蒸馏除去溶剂,得粗产物;然后将粗产物用快速柱色谱法纯化,洗脱剂为体积比1:1的石油醚和乙酸乙酯,即得目标产物D11,产率为71%。
具体反应式为:
目标产物D11的1H NMR(400MHz,CDCl3):δ7.91(t,8.8Hz,2H),7.61-7.50(m,4H),7.39-7.30(m,4H),7.20-7.19(m,2H),7.13-7.07(m,2H),7.05-7.01(m,1H),6.93(s,1H),6.88(s,1H),6.72(d,J=1.6Hz,1H),6.19(s,1H),4.61(t,J=9.2Hz,1H),3.47(ddd,J=16.4,11.4,4.0Hz,1H),3.32(d,1H),3.28(s,3H);
目标产物D11的13C NMR(100MHz,CDCl3):δ186.31(d,J=13.2Hz),136.90,132.44(d,J=2.3Hz),132.02(d,J=2.9Hz),131.81(d,J=8.5Hz),131.39,131.08(d,J=9.2Hz),129.06(d,J=11.3Hz),128.29(d,J=11.6Hz),124.88,121.17,120.39,119.33,116.99,110.97,109.03,102.48,53.43,45.85,38.61,34.05,33.35,29.72,29.03;
目标产物D11的31P NMR(162MHz,CDCl3):δ31.99.
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种吲哚类有机膦化合物的合成方法,其特征是:其包括以下步骤:
S1、以2-吲哚甲醛类化合物A和苯乙酮类化合物B为原料,溶于第一溶剂中,在碱催化剂条件下进行羟醛缩合脱水反应,得到吲哚烯酰基类化合物C;
反应路线如下:
其中,R1选自2-Me、3-Me、4-Me、2-Cl、3-Cl、4-Cl、H中的一种;Ar1选自2-MeC6H4、3-MeC6H4、4-MeC6H4、3-BrC6H4、4-MeOC6H4、naphthalene、thianaphthene、furan、pyrrole中的一种;
S2、将二苯基氧膦、步骤S1中得到的吲哚烯酰基类化合物C溶于第二溶剂中,在金属盐催化剂条件下进行加成反应,得到目标产物D;
反应路线如下:
2.根据权利要求1所述的吲哚类有机膦化合物的合成方法,其特征是:其步骤S1中,2-吲哚甲醛类化合物A和苯乙酮类化合物B的摩尔比为1:2~2:1mmol,2-吲哚甲醛类化合物A、第一溶剂和碱催化剂的用量之比为1mmol:5~15mL:1~2mmol。
3.根据权利要求1或2所述的吲哚类有机膦化合物的合成方法,其特征是:其步骤S1中,第一溶剂为乙醇、甲醇、二氯甲烷、乙酸乙酯中的一种。
4.根据权利要求1或2所述的吲哚类有机膦化合物的合成方法,其特征是:其步骤S1中,碱催化剂为0.5~1.5mol/L的NaOH溶液或KOH溶液。
5.根据权利要求1所述的吲哚类有机膦化合物的合成方法,其特征是:其步骤S1中,反应温度为0~室温,反应时间为1.5~3h。
6.根据权利要求1所述的吲哚类有机膦化合物的合成方法,其特征是:其步骤S2中,二苯基氧膦和吲哚烯酰基类化合物C的摩尔比为1:1~5:1mmol,吲哚烯酰基类化合物C、第二溶剂、金属盐催化剂的用量之比为1mmol:2~8mL:1~5mmol。
7.根据权利要求1或6所述的吲哚类有机膦化合物的合成方法,其特征是:其步骤S2中,第二溶剂为二氯甲烷、甲苯、N,N-二甲基甲酰胺、正己烷中的一种。
8.根据权利要求1或6所述的吲哚类有机膦化合物的合成方法,其特征是:其步骤S2中,金属盐催化剂为Cs2CO3、Na2CO3、NaHCO3、K2CO3、K3PO4、Na3PO4、Cu(OAc)2中的一种。
9.根据权利要求1所述的吲哚类有机膦化合物的合成方法,其特征是:其步骤S2中,反应温度为室温,反应时间为2~5h。
10.根据权利要求1所述的吲哚类有机膦化合物的合成方法,其特征是:其步骤S2中,用薄层色谱TLC监测反应进程,待反应物完全消失后,将反应液倒入水中,再用萃取剂萃取,合并萃取液;萃取液用干燥剂干燥,过滤、减压蒸馏,得粗产物;然后将粗产物用快速柱色谱法纯化,获得目标化合物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210801332.4A CN115010756A (zh) | 2022-07-08 | 2022-07-08 | 一种吲哚类有机膦化合物的合成方法 |
GB2304417.5A GB2620465A (en) | 2022-07-08 | 2023-03-27 | Synthesis method of indole organophosphorus compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210801332.4A CN115010756A (zh) | 2022-07-08 | 2022-07-08 | 一种吲哚类有机膦化合物的合成方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115010756A true CN115010756A (zh) | 2022-09-06 |
Family
ID=83082400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210801332.4A Pending CN115010756A (zh) | 2022-07-08 | 2022-07-08 | 一种吲哚类有机膦化合物的合成方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115010756A (zh) |
GB (1) | GB2620465A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008044909A (ja) * | 2006-08-18 | 2008-02-28 | Tokyo Institute Of Technology | 2−フタルイミド−3−ホスホノプロピオン酸エステル化合物及びその製造方法 |
CN101805375A (zh) * | 2010-03-26 | 2010-08-18 | 中国科学院上海有机化学研究所 | 一种高对映选择性催化合成手性膦化合物的方法 |
CN103709194A (zh) * | 2014-01-06 | 2014-04-09 | 苏州鹏旭医药科技有限公司 | 光学活性的羟基保护的脂肪族磷酸酯的制备方法 |
CN109456362A (zh) * | 2018-11-28 | 2019-03-12 | 湖南理工学院 | 一种以p(o)-h化合物高效制备含二芳基甲基取代有机膦酸酯的新方法 |
CN110467640A (zh) * | 2019-08-30 | 2019-11-19 | 南昌航空大学 | 一种吲哚或苯并咪唑-异喹啉酮稠合杂环衍生物的制备方法 |
-
2022
- 2022-07-08 CN CN202210801332.4A patent/CN115010756A/zh active Pending
-
2023
- 2023-03-27 GB GB2304417.5A patent/GB2620465A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008044909A (ja) * | 2006-08-18 | 2008-02-28 | Tokyo Institute Of Technology | 2−フタルイミド−3−ホスホノプロピオン酸エステル化合物及びその製造方法 |
CN101805375A (zh) * | 2010-03-26 | 2010-08-18 | 中国科学院上海有机化学研究所 | 一种高对映选择性催化合成手性膦化合物的方法 |
CN103709194A (zh) * | 2014-01-06 | 2014-04-09 | 苏州鹏旭医药科技有限公司 | 光学活性的羟基保护的脂肪族磷酸酯的制备方法 |
CN109456362A (zh) * | 2018-11-28 | 2019-03-12 | 湖南理工学院 | 一种以p(o)-h化合物高效制备含二芳基甲基取代有机膦酸酯的新方法 |
CN110467640A (zh) * | 2019-08-30 | 2019-11-19 | 南昌航空大学 | 一种吲哚或苯并咪唑-异喹啉酮稠合杂环衍生物的制备方法 |
Non-Patent Citations (4)
Title |
---|
D.A.BLINNR.S.BUTTON,等: "Addition of diphenylphosphine to Michael-type olefins: the preparation of phosphine-nitrile and phosphine-ester ligands", 《JOURNAL OF ORGANOMETALLIC CHEMISTRY》 * |
HUANG, ZHENJUN,等: ""Potassium Carbonate Promoted Nucleophilic Addition of Alkenes with Phosphites"", 《SYNLETT》 * |
TAN, JIAN-PING,等: ""Asymmetric synthesis of N-bridged [3.3.1] ring systems by phosphonium salt/Lewis acid relay catalysis"", 《NATURE COMMUNICATIONS》 * |
付建平,等: "环丁烯酮化合物高效合成喹啉衍生物的应用研究", 《化学通报》 * |
Also Published As
Publication number | Publication date |
---|---|
GB2620465A (en) | 2024-01-10 |
GB202304417D0 (en) | 2023-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1608074B (zh) | P-手性磷杂戊环和磷环化合物及其在不对称催化反应中的用途 | |
JP2007277256A (ja) | 水溶液中でのアルキンの環状三量化法 | |
JP2002506836A (ja) | パラジウム触媒によるカップリング反応 | |
US5274125A (en) | Chirale phosphines | |
CN112321481B (zh) | 一种手性吲哚类化合物及其制备方法 | |
US20040229846A1 (en) | P-chiral phospholanes and phosphocyclic compounds and their use in asymmetric catalytic reactions | |
CN111187298B (zh) | 一种c2-膦酰基亚甲基吲哚化合物及其制备方法和用途 | |
CN113583042A (zh) | 一种磷酰氟类化合物的制备方法 | |
CN115010756A (zh) | 一种吲哚类有机膦化合物的合成方法 | |
CN109897064B (zh) | 一种3-吲哚基-3-(磷酸二乙酯基)氧化吲哚化合物的制备方法 | |
US5514805A (en) | Assymetric synthesis process | |
WO2007036701A1 (en) | Ferrocenyl phosphite ligands for asymmetric catalysis and a method for their production | |
CN108467408B (zh) | 一种具有羟基苯基官能团的二芳基磷化合物及其制备方法 | |
CN101220058B (zh) | 手性和非手性pcn钳形钯化合物及合成方法和用途 | |
CN114907404A (zh) | 5-(2-(二取代膦基)苯基)-1-烷基-1h-吡唑膦配体及其制备方法和应用 | |
CN112675920A (zh) | 一类单手性中心催化剂及其制备和催化合成手性醇类化合物和手性α-烯丙醇的方法 | |
CN106243034B (zh) | 一种Pd/Ti催化四组分羰化偶联反应合成取代喹啉的方法 | |
Legrand et al. | Stereospecific Migration of P from N to C: Ring‐Expansion Reaction of Chiral Diazaphospholidine Oxides | |
CN114832862B (zh) | 一种偶联反应的催化组合物及其在制备异喹啉-1,3-二酮类化合物中的应用 | |
CN109867694A (zh) | 一种氧导向的7-炔基吲哚类化合物的合成方法 | |
CN109678862A (zh) | 一种多取代二苯乙烯基吲哚衍生物的制备方法 | |
CN111777478B (zh) | 一种临酰基苯胺磺酰胺类化合物的合成方法 | |
CN115651017A (zh) | 基于苄基硫醚类衍生物选择性制备苄基或烷基氧化膦化合物的方法 | |
JP2023176740A (ja) | 有機リン化合物の製造方法 | |
WO2020073209A1 (zh) | 一种三氟甲基烯基膦酸酯及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |